Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

25.19 +0.25 (+1.00%)
Official Closing Price Updated: 4:10 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Informs Investors of the Alto Neuroscience, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
News headline image
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal ↗
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207. 
Via Benzinga
News headline image
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock ↗
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 
Via Stocktwits
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
News headline image
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Via ACCESSWIRE
News headline image
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
News headline image
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud
Via ACCESSWIRE
News headline image
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
News headline image
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Nasdaq Down 2%; US Crude Stocks Increase ↗
 
Via Benzinga
News headline image
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform ↗
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
News headline image
Gold Moves Lower; AT&T Earnings Top Views ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.